Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alto Neuroscience, Inc. ANRO NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$26.33
+3.4%

Alto Neuroscience, Inc. (ANRO) is a Biotechnology company in the Healthcare sector, currently trading at $25.47. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is ANRO = $26 (+3.4% upside).

Valuation: ANRO trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25).

Net income is $63M (loss), growing at -34.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $151M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 15.69 (strong liquidity). Debt-to-assets is 2.4%. Total assets: $185M.

Analyst outlook: 7 / 8 analysts rate ANRO as buy (88%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 34/100 (Fail), Future 76/100 (Pass), Income ?/100 (Fail).

$26.33
▲ 3.38% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Alto Neuroscience, Inc., the average price target is $26.33, with a high forecast of $35.00, and a low forecast of $16.00.
Highest Price Target
$35.00
Average Price Target
$26.33
Lowest Price Target
$16.00

ANRO SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 76/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ANRO

~
VALUE Partial
50/100
ANRO trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25). Forward PEG -0.56 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $26, implying +2.1% from the current price $25. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ANRO: +0%/yr revenue is, -34.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ANRO: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 15.69 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
ANRO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
76/100
Analyst outlook: 7 / 8 analysts rate ANRO as buy (88%). Analyst consensus target is $26 (+2.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.64-25.17
Volume330.97K
Avg Volume (30D)277.51K
Market Cap$813.65M
Beta (1Y)2.06
Share Statistics
EPS (TTM)-2.19
Shares Outstanding$28.85M
IPO Date2024-02-02
Employees76
CEOAmit Etkin
Financial Highlights & Ratios
Gross Profit$-661K
EBITDA$-65.7M
Net Income$-63.24M
Operating Income$-66.36M
Total Cash$176.48M
Total Debt$4.41M
Net Debt$-172.08M
Total Assets$184.69M
Price / Earnings (P/E)-11.6
Analyst Forecast
1Y Price Target$28.00
Target High$35.00
Target Low$16.00
Upside+9.9%
Rating ConsensusBuy
Analysts Covering8
Buy 88% Hold 13% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS02157Q1094

Price Chart

Track all markets on TradingView
ANRO
Alto Neuroscience, Inc. ↗  ·  NYSE
Healthcare • Biotechnology
1.64 52WK RANGE 25.17

People Also View

DRTS
DRTS
Alpha Tau Medical Ltd.
$7.88
+0.64%
 DBVT
DBVT
DBV Technologies S.A.
$21.25
-1.80%
 CTNM
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$13.25
+2.16%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 CLLS
CLLS
Cellectis S.A.
$4.09
-1.68%
 SLN
SLN
Silence Therapeutics plc
$7.28
+18.95%
 ACIU
ACIU
AC Immune S.A.
$3.14
-1.57%
 AMRN
AMRN
Amarin Corporation plc
$15.20
+4.47%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message